UniversitätsSpital Zürich - Klinik für Gynäkologie
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vetter, Marcus
MATAO, NCT04111978 / 2019-002264-27: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting
3
540
Europe
Letrozole 2.5mg, Femara, Placebo
Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
10/25
10/30
SAKK 21/12, NCT02067741: CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Terminated
2
29
Europe
CR1447, 4-OHT
Swiss Group for Clinical Cancer Research
Metastatic Breast Adenocarcinoma, Breast Cancer
08/18
10/22
INVINCIBLE-4, NCT06358573: Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. -SAKK

Recruiting
2
54
Europe
INT230-6, neoadjuvant immuno-chemotherapy
Swiss Group for Clinical Cancer Research
Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
03/26
12/29
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
NCT03928210: Digoxin Induced Dissolution of CTC Clusters

Completed
1
58
Europe
Digoxin, Lenoxin Mite, DIGOXIN Juvisé
University Hospital, Basel, Switzerland, ETH Zurich - The Aceto Lab
Breast Cancer, Circulating Tumor Cells (CTCs)
12/23
12/23
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
DIVAN, NCT05783401: Digital Voice Analysis as a Measure of Frailty and Distress

Recruiting
N/A
100
Europe
Data acquisition: Speech acquisition, Data acquisition: G8 Screening tool, Data acquisition: Distress Thermometer
University Hospital, Basel, Switzerland
Frailty, Distress, Emotional
11/25
11/25
NCT04520672: Circulating Tumor Cells (CTC) in Cancer

Recruiting
N/A
3000
Europe
Blood samples, Samples from tumor draining vessels
University Hospital, Basel, Switzerland
Cancer
08/30
08/30
Samartzis, Eleftherios Pierre
No trials found
Grabolus, Robert
No trials found

Download Options